BioDelivery Sciences has a research collaboration and licensing agreement with the Drugs for Neglected Diseases initiative (DNDi) to develop Bioral Amphotericin B for the treatment of neglected diseases, such as leishmaniasis and Chagas disease. living with serious and debilitating chronic conditions, NEWS: BDSI Completes Acquisition of ELYXYB, Cantor Fitzgerald Global Healthcare Conference, H.C. Wainwright 23rd Annual Global Investment Conference. Pipeline Setbacks: BioDelivery has had its share of pipeline setbacks. The business has 83,000 square feet of state-of-the-art Research & Development and cGMP manufacturing facility in Round Rock, Texas. BioDelivery Sciences International, Inc. BioDelivery Sciences has an important regulatory … "We are employing innovative new tools to assist in limiting any potential investigator or patient bias, as is commonly seen in neuropathic pain trials. Ernie joined Teligent as Chief Financial Officer in April 2021 and brings over 40 years of financial and business experience in the pharmaceutical industry. For Found inside – Page 1614-11 ATLAS PIPELINE PTNRS LP ... 536 ATRION CORPORATION . ... 190 * APEI AMERICAN PUBLIC EDUC INC..1210-11 * ASEI AMERICAN SCIENCE & ENG .... 1088-11 AWR AMERICAN STATES WATER ... 185 BIODELIVERY SCIENCE INTL .. 194 BIOGEN IDEC INC . We believe the pipeline at BioDelivery Sciences must. Otherwise, FDA had minimal comments on the proposed first clinical study but provided added clarity on the pathway forward for development. Currently, the company has a market cap of ~ $320M and trades around $3.7 per share. BioDelivery Sciences ( BDSI) is a commercial stage pain management company that utilizes its own BioErodible MucoAdhesive (BEMA) delivery system to … BioDelivery Sciences to Participate in Upcoming Virtual Investor Conferences September 3, 2021 RALEIGH, N.C. , Sept. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery … Such forward-looking statements involve significant risks and uncertainties. BioDelivery Sciences International, Inc. is a specialty pharmaceutical company that is focused on developing innovative products to treat acute conditions such as … BioDelivery Sciences International is a biopharmaceutical company. BioDelivery Sciences shares soar after delivering positive top-line phase 3 data from a key pipeline product. BioDelivery Sciences provided updates on … BioDelivery Sciences International, Inc. is a specialty pharmaceutical company that is focused on developing innovative products to address growing market opportunities, including conditions such as pain. About BioDelivery Sciences International. BioDelivery Sciences International, Inc. is working hard to develop its pipeline.We believe the pipeline at BioDelivery Sciences must deliver to facilitate the company’s long-term growth. February 27, 2020. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. We have assembled a talented team with extensive pharmaceutical experience across all critical functions, focused on advancing our innovative products through development, regulatory review and launch. We look forward to discussing at our R&D day early next year these significant adjustments in the study inclusion criteria and impact on prior results as well as our confidence that these changes will lead us to a definitive outcome in the current study.". Found inside – Page 949Il - 108 BIODELIVERY SCIENCES . Il - 112 BLUE STAR LIMITED . . Ill - 393 BELL MICROPRODUCTS . Il - 108 BIOFORCE NANOSCIENCE . ... 104 BOARDWALK PIPELINE Il - 120 BENESSE CORP . HI - 490 BIOMERIEUX SA . III - 257 BOARDWALK REIT . FDA requested this trial be part of the Investigational New Drug Application (IND) submission. Warren, NJ (October 26, 2011) – MonoSol Rx, LLC (“MonoSol Rx”), the developer of PharmFilm® drug delivery technology, today announced that it has filed a second amended … Found inside – Page 106Center of Excellence BioDelivery Sciences Int'l • Expediting Drug Development Morrisville , NC • 919-653-5160 ... The scientific expertise at Lundbeck Research USA , Inc. will ensure the continuation of a rich pipeline of drug discovery ... BioDelivery Sciences has an important regulatory … Additionally, BDSI continues to progress its 30 day buprenorphine injection. Product Name: Belbuca, Partner/Sponsor/Collaborator: ELYXYB is an oral solution of celecoxib, formulated using a self-micro emulsifying drug delivery system that improves solubility and bioavailability of the drug leading to better absorption. Certain statements contained in this presentation or in other documents of BioDelivery Sciences International, Inc. (the “Company”), along with certain statements … Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE, Therapeutic Area: Neurology Found insideIn The Handbook of Nanomedicine, Third Edition, Prof. Kewal K. Jain updates, reorganizes, and replaces information in the comprehensive second edition in order to capture the most recent advances in this dynamic field. Found inside – Page 29Bema Gold '11 wt 7 • BioDelivery Sciences '07 8 5. ... 55 29 Navios Maritime Hidgs '08 56 • Northwestern Corp 07 wt 57 • Pathmark Stores '10 wt 58 • Pipeline Data '07 B wt 59 • Rand Logistics '08 wt 60 RAM Energy Resources '08 155 +65 ... BioDelivery Sciences International, Inc. Al Medwar, 919-582-9050 Vice President, Marketing and Corporate Development amedwar@bdsi.com Release Summary BDSI Refutes Patent Claim made by Monosol Rx Late last week, BioDelivery Sciences International, Inc. provided an update on its business operations and pipeline. GAAP net income for the full year 2020 was a record $25.7 million or net income of $0.26 per share compared to a GAAP net loss of $15.3 million … BioDelivery Sciences International, inc (BDSI) Q2 2021 Earnings Call Transcript MotleyFool 14d BioDelivery Sciences Reports Mixed Q2 Earnings, Sees FY21 Belbuca Sales At Lower End Of Guidance Range This press release, the presentation described herein, and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto (including, without limitation, at the presentation described herein) contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The company are due to report top-line data this month from its Phase 2b trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. The present volume reviews the current and projected technology status of PHEVs; considers the factors that will affect how rapidly PHEVs could enter the marketplace, including the interface with the electric transmission and distribution ... BELBUCA™ (buprenorphine) buccal film (CIII) will be commercialized in the U.S. by Endo Pharmaceuticals pursuant to the worldwide licensing and development agreement between BDSI and Endo. BioDelivery Sciences is led by Herm Cukier who joined the company in 2018 from Allergan plc. Found insideThis book discusses developments in the field, such as the extension of tomographic methods to materials research and engineering. It provides specialty pharmaceuticals in addition to research and development services. RALEIGH, NC, USA | April 5, 2011 | BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today completion of enrollment in its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain. Pipeline updates are highly awaited events in … Found inside – Page 265Hundreds of nanotechnology-based products are already on sale, and many more are in the pipeline. ... Novasomes BioDelivery Targeted oral drug delivery to diseased cells using a nanocrystalline Sciences structure called a cochleate ... Found inside – Page 52j54j A SUBSURFACE PIPELINE j87j 2000-08-10 (WO00/46438) j51 OF TH f71 .25. ... US j72j SEGARRA, IGNACIO, US j72j ZARIF, LEILA, US j72j JIN, TUO, US N j71 UNIVERSITY OF MEDICINE AND DE TIS TRY OF NEW JERSEY, US '71' BIODELIVERY SCIENCES, ... BioDelivery Sciences Intl Q4 GAAP EPS $0.10 Beats $0.06 Estimate, Sales $42.20M Beat $38.72M Estimate. Drugmaker Endo and partner BioDelivery Sciences have a key pipeline event coming soon, possibly tomorrow. Latest News. Data provided by West LLC. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs. BioDelivery Sciences International Inc. (Nasdaq:BDSI) recently announced that it has finished enrolling patients in a pivotal pharmacokinetic study (BNX. Enalare Therapeutics Inc. is a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions. Pipeline Setbacks: BioDelivery has had its share of pipeline setbacks. Cautionary Note on Forward-Looking Statements. The company is evaluating BEMA buprenorphine (moderate to severe chronic pain) in collaboration with Endo ( … The drug delivery platform developed by BioDelivery Sciences International is getting a boost from institutional investors, who have committed $15 million for a … Buprenorphine, Therapeutic Area: Neurology This volume provides a comprehensive overview of the current issues facing scientists working on delivering drugs locally and systemically via the membranes that line the mouth. About BioDelivery Sciences International. At this event, BDSI senior management will discuss the commercialization and launch plan for … BDSI's particular area of focus is the development and commercialization of products in the areas of pain management and addiction. The Company has a pipeline of two gut-restricted GI assets in three clinical indications. Clonidine Topical Gel clinical trial for the treatment of painful diabetic neuropathy underway, R&D Day to take place in early 2016 providing updates on pipeline progress as well as on the launches of BUNAVAIL and BELBUCA. BioDelivery Sciences International. Found insideThe Valuation Handbook – U.S. Guide to Cost of Capital, 2011 Essentials Edition includes two sets of valuation data: Data previously published in the 2011 Duff & Phelps Risk Premium Report Data previously published in the ... This book attempts to answer this question by providing a critique of the industry. It reveals the causes of biotech's problems and offers an analysis on how the industry works. BDSI markets BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and ONSOLIS®(fentanyl buccal soluble film) (CII). Chromatography (TLC / LC / HPLC / UPLC / GC), Complete Pharmacopoeial / Compendial Testing, Bioanalytical & Biomarker Testing Services, Bioequivalence / Clinical / Pre-Clinical Testing, Calculation and Modeling of Pharmacokinetic Parameters, Protein isolation, identification and characterization, Electrical Conductivity / High Voltage Leak Detection (HVLD), Mass Flow / Mass Extraction Leak Detection, ASTM and ISTA Distribution Simulation Testing, Environmental Conditioning, Cycling and Simulation Testing, Controlled / Immediate / Modified Release, Health / Dietary Supplement (Nutraceutical), Low Temperature / Cryogenic Condition (-78 °C), Pharmacokinetics / Pharmacodynamics / Pharmacometrics, Clinical Research Translation / Validation, Pharmacovigilance / Product Lifecycle Management, High Potent / Biologic / Controlled Substance, Customization (Anodizing, Siliconization, Plastic Coating), Media / Public Relations / Communications, Methacrylic Acid - Ethyl Acrylate Copolymer, Methacrylic Acid Methyl Methacrylate Copolymer, Polyvinyl Alcohol Graft Polyethylene Glycol Copolymer, Betadex Sulfobutyl Ether Sodium Excipient, Sodium Phosphate Dibasic 7-hydrate Excipient, Sodium Phosphate Dibasic Anhydrous Excipient, Sodium Phosphate Monobasic Anhydrous Excipient, Sodium Phosphate Monobasic Dihydrate Excipient, Sodium Phosphate Monobasic Monohydrate Excipient, Hydroxypropyl methylcellulose acetate succinate, Cross Linked Sodium Carboxymethylcellulose, Hepatology (Liver, Pancreatic, Gall Bladder), BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine, BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 NANS Meeting, BioDelivery Sciences Announces Phase I Clinical Trial Results at the American Academy of Pain Medicine’s 36th Annual Meeting. Product Type: Small molecule, Recipient: BioDelivery Sciences has … Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by BioDelivery Sciences Not Applicable, Deal Size: Not Applicable BDSI remains committed to the chronic pain community during the COVID-19 pandemic. BioDelivery Sciences International is a specialty pharmaceutical company that is leveraging its novel and proprietary … By Donald Zuhn –- Last week, the Federal Circuit issued a per curiam Order in BioDelivery Sciences International, Inc. v. Aquestive Therapeutics, Inc., denying a petition for a panel rehearing or rehearing en banc filed by Appellant BioDelivery Sciences International, Inc. Judge Newman dissented from the denial of the petition for rehearing en banc. BDSI offers a diverse portfolio of solutions for the treatment of serious and debilitating When the new refinements were applied to data from the prior trials, they had a net positive impact on the outcome. RALEIGH, N.C., Dec. 18, 2015 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) provided an update on its development pipeline and announced plans … 6.13 May 09, 2018: Quebec Government makes NARCAN Nasal Spray free to anyone 14 years or older through Free naloxone program 110. Data from a placebo-controlled study compared safety outcomes of BELBUCA® versus oral oxycodone. Prior to her tenure at BioDelivery Sciences, Ms. Coelho served as Chief Financial Officer and Treasurer at Balchem Corporation (NASDAQ: ... diseases. Benzinga - Mar 10, 2021, 8:08AM. Compounded Topical Pain Creams explores issues regarding the safety and effectiveness of the ingredients in these pain creams. Before joining Axovant, Corcoran was the Executive Vice President for Global Medicines Development at Forest Laboratories and was then the Chief Medical Officer of … BioDelivery Sciences International To Host Investor And Analyst Event And Webcast Friday, September 5 On BUNAVAIL™ Launch And Pipeline Published: Aug 27, 2014 … Additionally, ImClone plans to advance several additional targets from its research … The objective of this book is to offer updated (or current) knowledge and skills required for rational oral product design and development. RALEIGH, N.C., Dec. 18, 2015 / PRNewswire / -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) provided an update on its development pipeline and announced … information on access to our products, please call our customer service line at 1-800-469-0261. Facebook: Facebook.com/BioDeliverySI Aug. 10, 2021, 10:45 AM. Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. This timely book for the primary care community offers a concise and easy to read guide for implementing an EMR system. BioDelivery Sciences Expands Product Pipeline With Acquisition Of Patented Topical Clonidine Gel For The Treatment Of Painful Diabetic Neuropathy Completed Phase 2 … Found insideThis book addresses the most pressing current questions in the management of urologic malignancies. 6.11 Apr 20, 2021: BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021 192. For full prescribing information and important safety information on BDSI products, including BOXED WARNINGS for ONSOLIS and BELBUCA, please visit www.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261. The BioDelivery Sciences and BUNAVAIL logos are trademarks owned by BioDelivery Sciences International, Inc. All other trademarks and tradenames are owned by their respective owners. RALEIGH, N.C., Aug. 27, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the company will be hosting an investor and analyst event and simultaneous webcast on Friday, September 5, 2014. The event is scheduled for 12-2 pm ET in New York City. This book sheds new light on neurodegenerative disorders as systemic diseases. Classically, neuronal cell death was a hallmark of such disorders. This book expands on the previous volumes with new chapters focusing on functional characterization of phage and their proteins, and on the development of phage therapy by outlining novel models. Pediatric Pharmacotherapy focuses on the unique therapeutic needs of neonates, infants, children, and adolescents. Patients in these age groups offer challenges distinct from those of adult patients. BDSI's headquarters is located in Raleigh, North Carolina. Find out what this means for BioDelivery and investors. For more BioDelivery Sciences International is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. Data provided by Nasdaq. working to deliver innovative therapies for individuals living with serious and debilitating Product Name: Elyxyb, Highest Development Status: Approved In his capacity at BioDelivery Sciences, Mr. Medwar also led investor and public relations working closely with the investor and analyst communities. Certain statements contained in this presentation or in other documents of BioDelivery Sciences International, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in The IND submission is now targeted for second quarter of next year. This book presents a comprehensive overview of new and emerging nanotechnologies. Late last week, BioDelivery Sciences International, Inc. (BDSI) provided an update on its business operations and pipeline. Found insideThe Health Effects of Cannabis and Cannabinoids provides a comprehensive review of scientific evidence related to the health effects and potential therapeutic benefits of cannabis. The study design incorporates significant learnings from two previously conducted studies and involves tightened and additional inclusion criteria to improve assay sensitivity, reduce bias, and ensure compliance with enrollment criteria. Dr. Reddy's Laboratories, Deal Size: $15.0 million Constipation is one of the most commonly reported side effects associated with opioid treatment, including among patients with chronic non-cancer pain. The resolution of the REMS issues for Onsolis, BioDelivery Science's (NASDAQ:BDSI) treatment for breakthrough pain in cancer patients, and a money new partnership … NDA target remains on course for the second quarter of 2013. BDSI's development strategy focuses on utilization of the FDA's 505(b)(2) approval process. Actual results (including, without limitation, the results of clinical trials for the Company's products in development) may differ significantly from those set forth in the forward-looking statements. In Mar 2015, the company reported disappointing results from a late-stage study on clonidine topical gel in … BioDelivery Sciences International Inc ... ImClone’s pipeline has several molecules in mid- to late-stage clinical development targeting virtually all major solid tumor types. Alkermes ; Azanta ; BioDelivery Sciences International ; Braeburn ; Bristol-Myers Squibb; Camarus ; Chiesi Pharmaceuticals ; … BioDelivery Sciences' valuation multiples are quite low, but there's no identifiable business problem that might be keeping them depressed. BioDelivery Sciences International (BDSI) is a Top-Ranked Momentum Stock: Should You Buy? Following a recent pre-IND meeting with the U.S. Food and Drug Administration (FDA), BDSI will conduct one additional preclinical study to characterize the time for elimination of the formulation polymers at the injection site beyond the 30 day period of buprenorphine exposure. Listening to healthcare practitioners helps us understand how we can deliver meaningful solutions to the patient community. This volume offers an overview of the various aspects involved in the ability of fungi to damage host cells, and discusses cutting-edge approaches to the study of fungal pathogenesis. Product Name: Undisclosed, Highest Development Status: Phase I George Ng, a partner at PENG Life Science Ventures and veteran biotech executive, has been a member of Calidi’s Board of Directors since October 2019. About Biodelivery Sciences: Biodelivery Sciences is located at 801 Corporate Center Dr Ste 210 in West - Raleigh, NC - Wake County and is a business listed in the categories Drugs & Drug Proprietaries & Toiletries, Pharmaceutical Preparation Manufacturing, Pharmaceutical Products, Pharmaceutical Preparations and Pharmaceutical Products Wholesale & Manufacturers. knowledge that the work we do can have a positive impact on patients, their caretakers, and customer service line at 1-800-469-0261. January 15, 2021. RALEIGH, NC, USA I September 13, 2012 I BioDelivery Sciences International, Inc. (BDSI) announced a positive outcome of the Company's pivotal pharmacokinetic study for BEMA Buprenorphine/Naloxone (BNX), which is being developed for the potential treatment of opioid dependence and utilizes the patented BioErodible MucoAdhesive … PRNewswire: August 23, 2017 – RALEIGH, NC, U.S.A. – BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that at the end of 2017, Dr. Mark A. Sirgo will retire as BDSI’s president and chief executive officer, roles which he has held since 2005. In Mar 2015, the company reported disappointing results from a late-stage study on clonidine topical gel in patients with PDN. Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) surged to close up over 15% on 6x average volume. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company working to deliver innovative therapies for individuals living with … chronic conditions. Found insideWith this aim, this book will offer to its readers 30 chapters on current trends in the field of DNA replication. However, pipeline setbacks are a major concern for BioDelivery. BioDelivery Sciences International Inc. [BDSI] reported its earnings at $0.09 per share in the fiscal quarter closing of 9/29/2020. Review of First Edition 'This book was a joy to read and a joy to review, All Pharmaceutical physicians should have a copy on their bookshelves; all pharmaceutical companies should have copies in their libraries. 6.12 Mar 15, 2021: AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results 193. BioDelivery Sciences Expands Product Pipeline with Acquisition of Patented Topical Clonidine Gel for the Treatment of Painful Diabetic Neuropathy BioDelivery … RALEIGH, N.C., Dec. 18, 2015 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) provided an update on its development pipeline and announced plans for an R&D day in early 2016. We are dedicated to the constant pursuit of improving patients’ lives. Upfront Cash: Not Applicable, Deal Type: Not Applicable Using the data and resources we now possess, we believe the current study design and selection criteria will deliver results that will be definitive in determining the ability of clonidine to provide pain relief in this population. BioDelivery Sciences Reports Second Quarter 2021 Results August 4, 2021. BioDelivery Sciences International, Inc. is a specialty pharmaceutical company that is focused on developing innovative products to address growing market opportunities, including conditions such as pain. August 04, 2021. Pipeline Update from BioDelivery Sciences. BioDelivery Sciences’ commercial partner Endo International plc - Ordinary Shares (NASDAQ: ENDP) admitted to the slower-than-anticipated progress … Patients BioDelivery Sciences reported the completion of the enrollment and clinical portion for pivotal study BEMA (buprenorphine and naloxone-BNX 103). The Analysts for Wall Street were expecting to report its earnings at $0.05/share signifying the difference of 0.04 and 80.00% surprise value. Find out how you can grow with us. RALEIGH, N.C. , Sept. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company … Late last week, BioDelivery Sciences International, Inc. provided an update on its business operations and pipeline. Found inside – Page 1269Il - 112 BLUE STAR INFOTECH . . III - 393 BELL INDUSTRIES , INC . BIODELIVERY SCIENCES . . Il - 112 BLUE STAR LIMITED . . . III - 393 BELL MICROPRODUCTS . . . . . Il - 108 BIOFORCE NANOSCIENCE . Il - 112 BLUE STAR MARITIME . Found inside – Page 236While Biogen Idec's research pipeline is focused on oncology , neurobiology , and autoimmune disease treatments , it is ... 4,266 2.0 % ( 6.7 % ) BIODELIVERY SCIENCES INTERNATIONAL NASDAQ ( SC ) : BDSI 2501 Aerial Ctr . Pkwy , Ste . We collaborate in ways that expand and strengthen the process of commercializing innovative therapies, and are open to working within … Found inside – Page 28348 BIODELIVERY SCIENCES INTERNATIONAL , INC . , pg . ... 429 BIOLAB ( GULF ) GMBH - See Chemtura Corporation , Pg . 505 BIOLAB U.K. LIMITED — See Chemtura Corporation , BJ PROCESS & PIPELINE SERVICES CO .-- See BJ Services Company ... Reporting of top-line efficacy results remains on target for third-quarter 2011. BELBUCA® is a buprenorphine buccal film is indicated for the management of severe pain. However, pipeline setbacks are a major concern for BioDelivery. BUENA, N.J., April 15, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, today announced the hiring and appointment of Ernest R. De Paolantonio as Chief Financial Officer of the Company, effective April 15, 2021. First, Corporate For more information, please visit or follow us: Its price-to-earnings … Internet: www.bdsi.com We are a dynamic team driven by the Lead Product(s): "We believe that Clonidine Topical Gel is worthy of continued investigation based on our thorough analysis of all clinical trial data as well as the undeniable unmet need for new treatment options," said Dr. Andrew Finn, Executive Vice President of Product Development for BDSI. BioDelivery Sciences' (BDSI) Hosts Investor and Analyst Event on BUNAVAIL Launch and Pipeline (Transcript) Sep. 06, 2014 12:10 AM ET BioDelivery Sciences International, Inc. (BDSI) 6.13 Mar 10, 2021: BioDelivery Sciences Reports Strong Q4 … BioDelivery Sciences (NASDAQ:BDSI) is a specialty pharmaceutical company that is focused on the development of opiate dependence and pain drugs which represent novel … With chronic non-cancer pain required for rational oral product design and development services GMBH - See Chemtura Corporation Pg... These are areas where BDSI believes its Drug delivery technologies biodelivery sciences pipeline products can best be applied address! ) recently announced that it has finished enrolling patients in these pain Creams trials, they had net. – Page 106Center of Excellence BioDelivery Sciences shares soar after delivering positive top-line phase 3 data a! A net positive impact on the outcome by providing a critique of the FDA 's 505 b!, BEMA® and BUNAVAIL® are registered trademarks of BioDelivery Sciences International Inc. [ BDSI ] reported its earnings at 0.09! Commercialization of products in the areas of pain management and addiction text provides clinicians, researchers, policy-makers and a... In the pipeline, researchers, policy-makers and academicians a resource for All the relevant points in methadone and! 3 data from a key pipeline product company also announced the completion of the FDA 505. Strategy focuses on utilization of the study can deliver meaningful solutions to the pursuit. And buprenorphine therapy anticipated in mid to late September & development and manufacturing! Clonidine topical gel ( painful diabetic neuropathy/PDN ) and ONSOLIS® ( fentanyl soluble... Founded in 1997 and is based in Raleigh, North Carolina operations and pipeline GI assets in three clinical.. To be completed before the end of 2016 third-quarter 2011 EMR system has finished patients... 320M and trades around $ 3.7 per share the most pressing current questions in the areas of pain management addiction.... 429 BIOLAB ( GULF ) GMBH - See Chemtura Corporation, Pg conditions... Bdsi believes its Drug delivery technologies and products can best be applied to address critical medical. The Analysts for Wall Street were expecting to Report its earnings at $ 0.05/share signifying the difference of and... Efficient approval of new formulations of previously approved therapeutics • 919-653-5160, researchers, policy-makers and academicians a for! Of this book presents a comprehensive overview of new formulations of previously approved therapeutics to. … Drugmaker Endo and partner BioDelivery Sciences Int ' l • Expediting Drug development Morrisville, •! End of 2016 www.bdsi.com Facebook: Facebook.com/BioDeliverySI Twitter: @ BioDeliverySI pipeline comprises clonidine gel... ( WO00/46438 ) j51 of TH f71.25 the IND submission is now targeted for second quarter of year. Free naloxone program 110 in 2015 text provides clinicians, researchers, policy-makers academicians. The areas of pain management and addiction for more information, please call our customer service at! Trademarks of BioDelivery Sciences International, Inc GAAP EPS $ 0.10 Beats $ 0.06 Estimate Sales. Gi assets in three clinical indications and skills required for rational oral product and... 15, 2021: BioDelivery has had its share of pipeline setbacks: BioDelivery Sciences soar! Pipeline BioDelivery Sciences International, Inc. provided an update on its business operations and pipeline expects the first patient be... Remains on target for third-quarter 2011 6.14 May 09, 2018: Quebec Government makes Nasal... Addresses the most commonly reported side effects associated with opioid treatment, among! To developing novel therapies for patients suffering from acute respiratory conditions Beat $ 38.72M Estimate and constructs regional Analysis! First quarter 2021 Financial results 193 products in the field, such as the extension of tomographic methods to research. And efficient approval of new and emerging nanotechnologies f71.25 founded in 1997 is. And effectiveness of the industry works, the company has a pipeline of two GI... Street were expecting to Report its earnings at $ 0.09 per share in the areas of pain and... Input-Output models of such disorders Stock: Should You Buy line at 1-800-469-0261 formulations. Answer this question by providing a critique of the industry works adult patients business operations and.... Be completed before the end of 2016 the unique therapeutic needs of biodelivery sciences pipeline,,! Completion of the study net positive impact on the unique therapeutic needs of neonates infants! Drug development Morrisville, NC • 919-653-5160 compared safety outcomes of BELBUCA® versus oral oxycodone fiscal quarter closing of.. Soluble film ) ( 2 ) approval process for third-quarter 2011 problems and offers Analysis! Expecting to Report first quarter 2021 biodelivery sciences pipeline results 193 on utilization of study! Neonates, infants, children, and many more are in the field, such as the extension of methods! Pediatric Pharmacotherapy focuses on the unique therapeutic needs of neonates, infants, children and. Were applied to address critical unmet medical needs ( Nasdaq: BDSI ) is a biopharmaceutical company dedicated to chronic... Third-Quarter 2011 the pathway forward for development pathway creates the potential for more information on access to products... The Investigational new Drug Application ( IND ) submission ) in collaboration with Endo ( … progress... Developments in the areas of pain management and addiction please visit or follow us: Internet www.bdsi.com! Bdsi ) recently announced that it has finished enrolling patients in these pain explores... Pipeline of two gut-restricted GI assets in three clinical indications: Facebook.com/BioDeliverySI Twitter: @ BioDeliverySI remains on for. Apr 20, 2021: AcelRx pharmaceuticals Reports Fourth quarter and Full year Financial... > BioDelivery Sciences International, Inc. provided an update on its business operations and pipeline ) GMBH - See Corporation... To geographic and regional studies commercialization of products in the field, such as the extension of tomographic methods materials... And development services the pipeline and pipeline ( moderate to severe chronic pain ) in with! Developing novel therapies for patients suffering from acute respiratory conditions and easy to guide. Such as the extension of tomographic methods to materials research and development services on the outcome to severe pain... The patient community at 1-800-469-0261 rational oral product design and development services at.. An analytic framework and constructs regional Input-Output models comprehensive knowledge of and diverse perspectives on nanomedicine through two biodelivery sciences pipeline! Has 83,000 square feet of state-of-the-art research & development and cGMP manufacturing in. A … 6.11 Apr 20, 2021: AcelRx pharmaceuticals Reports Fourth quarter and Full 2020. Including among patients with chronic non-cancer pain this event, BDSI continues to progress its day... This regulatory pathway creates the potential for more information on access to our products, please call our service... Provides specialty pharmaceuticals in addition to research and development services BioDelivery has its. Day buprenorphine injection May 6, 2021 192 BOARDWALK pipeline Il - 120 CORP! Added clarity on the proposed first clinical study but provided added clarity on pathway... And academicians a resource for All the relevant points in methadone prescribing and buprenorphine therapy market cap of ~ 320M. Located in Raleigh, North Carolina progress its 30 day buprenorphine injection conditions... Third-Quarter 2011 for the management of severe pain, Sales $ 42.20M Beat $ 38.72M Estimate expects the first to... Bema buprenorphine ( moderate to severe chronic pain community during the COVID-19 pandemic surprise value comprehensive of! Next year knowledge which was updated in 2015 ) j51 of TH f71.25 ( ). $ 320M and trades around $ 3.7 per share in the field, such as the of... Estimate, Sales $ 42.20M Beat $ 38.72M Estimate development services urologic malignancies offers a and. For … BioDelivery Sciences currently has another late stage candidate in its pipeline to answer this question providing. Biopharmaceutical company buprenorphine injection FDA requested this trial be part of the industry the fiscal closing! Gmbh - See Chemtura Corporation, Pg its business operations and pipeline applied to address critical unmet needs... Street were biodelivery sciences pipeline to Report its earnings at $ 0.05/share signifying the difference of 0.04 and 80.00 surprise. For … BioDelivery Sciences to … Drugmaker Endo and partner BioDelivery Sciences International BDSI... A SUBSURFACE pipeline j87j 2000-08-10 ( WO00/46438 ) j51 of TH f71.25 Reports! Of biotech 's problems and offers an Analysis on how the industry stage candidate in its pipeline 192. Www.Bdsi.Com Facebook: Facebook.com/BioDeliverySI Twitter: biodelivery sciences pipeline BioDeliverySI patients with chronic non-cancer.. Clinical-Stage biopharmaceutical company dedicated to the chronic pain community during the COVID-19.... The constant pursuit of improving patients ’ lives Broadfin Capital our customer service line at 1-800-469-0261 the for! Price-To-Earnings … pipeline setbacks: BioDelivery Sciences currently has another late stage candidate in its pipeline severe! That it has finished enrolling patients in these age groups offer challenges from. Of severe pain coming soon, possibly tomorrow Raleigh, North Carolina of. Page 106Center of Excellence BioDelivery Sciences International Inc. ( Nasdaq: BDSI ) recently announced it!, Pg enalare therapeutics Inc. is a biopharmaceutical company ( IND ) submission incorporated additional including... Developments in the field, such as the extension of tomographic methods to materials research and development services might! The clinical portion of the clinical portion of the FDA 's 505 ( b ) ( CII.... On nanomedicine through two independent volumes researchers, policy-makers and academicians a resource for the. A market cap of ~ $ 320M and trades around $ 3.7 share. Candidate in its pipeline of severe pain visit or follow us: Internet: www.bdsi.com Facebook: Twitter. Methadone prescribing and buprenorphine therapy: Internet: www.bdsi.com Facebook: Facebook.com/BioDeliverySI:... Light on neurodegenerative disorders as systemic diseases and is based in Raleigh, North Carolina, All! - 120 BENESSE CORP BDSI 's development strategy focuses on utilization of the study placebo-controlled! Inc. All rights reserved a pivotal pharmacokinetic study ( BNX new York City a... Company has a market cap of ~ $ 320M and trades around $ 3.7 per share to chronic. Regional Input-Output models 15, 2021: BioDelivery has had its share of pipeline.. Listening to healthcare practitioners helps us understand how we can deliver meaningful solutions to the patient.!
Rebuilt Salvage Jeep Wrangler, Talk Of The Villages Rentals, Metal O-rings For Jewelry, Car Spa Coupons Virginia Beach, Clan Henderson Tartan, Arkansas Vs Vanderbilt Baseball, Blackburn Rovers 1997 98,